Stakeholders withdraw support for pharmaceutical manufacturing projects quietly before they withdraw it formally. A schedule for the wider project and portfolio delivery agenda without a critical path is a wish list with dates. It concentrates on the parts of this strand of project and portfolio delivery that determine outcomes and treats the rest proportionately. Mature organisations treat pharmaceutical manufacturing projects as a standing capability rather than a project that finishes. Participants apply this aspect of project and portfolio delivery to their own project throughout, so the output is directly usable. The outcome is a practitioner who can hold a position on this area of project and portfolio delivery and revise it on evidence. It is pitched for practitioners with responsibility for pharmaceutical manufacturing projects, not for observers of it. What blocks progress on this part of project and portfolio delivery is usually unclear ownership rather than unclear intent. The programme closes with an action plan for the project and portfolio delivery discipline that each participant writes for their own organisation.
Expected Learning Outcomes
✓
Recover pharmaceutical manufacturing projects when it is behind, without pretending it is not.
✓
Design the governance and decision rights for pharmaceutical manufacturing projects.
✓
Reduce avoidable variation in how pharmaceutical manufacturing projects is carried out across teams.
✓
Define the scope of pharmaceutical manufacturing projects precisely, including what is explicitly excluded.
✓
Build the reporting on pharmaceutical manufacturing projects that gives early warning rather than reassurance.
✓
Anticipate the objections that pharmaceutical manufacturing projects will attract internally and answer them in advance.
✓
Define the scope and boundaries of pharmaceutical manufacturing projects so that responsibility for it is unambiguous.
Who Should Attend
✓
Staff seconded into improvement work on pharmaceutical manufacturing projects.